| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77758-0.5mg | |||
| BSA Free | NB100-77758SS | |||
| Azide and BSA Free | NBP2-80627 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-55376SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-145SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-48337SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-36561SS | |||
| Azide and BSA Free | NBP2-80818 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| IHC-Prediluted | NBP2-44808 | |||
| Azide and BSA Free | NBP2-34689-0.1mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-724SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-725SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-78039SS | |||
| Azide and BSA Free | NBP2-80921 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-48338SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-25196SS | |||
| Azide and BSA Free | NBP2-80634 | |||
![Immunocytochemistry/Immunofluorescence: CD14 Antibody (M5E2) [NB100-77758] - Representative immunostaining of CD14 (red) in adult human lung tissue sample with nuclei counterstained blue. This image was submitted by customer review. Image from the Alexa Fluor 647 version of this antibody.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Immunocytochemistry-Immunofluorescence-NB100-77758-img0009.jpg "Immunocytochemistry/Immunofluorescence: CD14 Antibody (M5E2) [NB100-77758] - Representative immunostaining of CD14 (red) in adult human lung tissue sample with nuclei counterstained blue. This image was submitted by customer review. Image from the Alexa Fluor 647 version of this antibody.")
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - A surface stain was performed on human peripheral blood monocytes with CD163 (EDHu-1) antibody NB110-40686APC and a matched isotype control NBP2-27287APC. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. A co-stain was performed with NB100-77758AF488.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: CD14 Antibody (M5E2) [NB100-77758] - Human lung tissue was stained with FITC-conjugated CD14 (Green) for overnight. Image from the Alexa Fluor 488 version of this antibody.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Immunocytochemistry-Immunofluorescence-NB100-77758-img0008.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Human peripheral blood monocytes stained with M5E2 APC](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0001.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Analysis using the FITC conjugate of NB100-77758. Staining of Human peripheral blood monocytes with M5E2 FITC.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0004.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Analysis using the PE conjugate of NB100-77758. Staining of CD14 in human PBMC using anti-CD14 antibody conjugated with PE. Image from verified customer review.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0005.jpg)
![Flow Cytometry: CD14 Antibody (M5E2) [NB100-77758] - Analysis using PE conjugate of NB100-77758. A cell surface stain was performed on hPBMCs with ILT5 antibody (MM0413-9S32) NBP2-11729 (top image) and a matched isotype control NBP2-27287 (bottom image). Cells were incubated in an antibody dilution of 1:200 for 20 minutes at room temperature. Both antibodies were conjugated to APC. A co-stain was performed using CD14 antibody (M5E2) NB100-77758PE.](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Flow-Cytometry-NB100-77758-img0006.jpg)
![Dual RNAscope ISH-IHC: CD14 Antibody (M5E2) [NB100-77758] - TNFA mRNA (red) and CD14 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human malignant lymph node. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-TNFA and CD14 antibody (M5E2) at 1:200 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/CD14-Antibody-M5E2-Dual-RNAscope-ISH-IHC-NB100-77758-img0010.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Total protein from HeLa, MCF7 and mouse brain was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TARDBP in 1% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0012.jpg "Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Total protein from HeLa, MCF7 and mouse brain was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TARDBP in 1% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with TDP-43/TARDBP Antibody conjugated to Alexa Fluor 488 (NB110-55376AF488) at 10 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-TARDBP at 2 ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0011.jpg)
![Immunohistochemistry-Paraffin: TDP-43/TARDBP Antibody [NB110-55376] - Analysis of FFPE human placenta using TDP-43 antibody at 1:250 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Nuclear staining was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunohistochemistry-Paraffin-NB110-55376-img0010.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - TARDBP antibody was tested in HeLa WCE.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0004.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Cells were transfected with the pCMV6-ENTRY control or pCMV6-ENTRY TARDBP cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-TARDBP.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - TARDBP antibody was tested in MCF-7 cells with DyLight 488 (Green). Nuclei and alpha-tubulin were counterstained with DAPI (Blue) and DyLight 550 (Red).](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - Analysis using the DyLight 550 conjugate of NB110-55376. Staining of Human iPS derived neurons, fixed in 4% formaldehyde solution. NB110-55376R was diluted 1:200. All antibodies were diluted in PBS/BSA 3% (w/v) ) Triton X-100 0,3 % (v/v). Images taken by an Arrayscan (Cellomics). Blue dots in TDP staining is Hoechst.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - Subcellular distribution of TDP-43 and CWC22 in control DRG sensory neurons. TDP-43 was stained diffusely in the nucleus, excluding SMN foci in sensory neurons. Scale bar: 10 um. Image collected and cropped by CiteAb from the following publication (//dmm.biologists.org/lookup/doi/10.1242/dmm.028225) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0013.jpg)
![Immunohistochemistry: CD36 Antibody [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), and DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 um. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) and TLR2 (green). Scale bar = 5 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-49472-8), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD36-Antibody-Immunohistochemistry-NB400-145-img0009.jpg "Immunohistochemistry: CD36 Antibody [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), and DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 um. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) and TLR2 (green). Scale bar = 5 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-49472-8), licensed under a CC-BY license.")
![Simple Western: CD36 Antibody [NB400-145] - Image shows a specific band for CD36 in human adipose lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/CD36-Antibody-Simple-Western-NB400-145-img0007.jpg)
![Western Blot: CD36 Antibody [NB400-145] - Detection of CD36 in human adipocyte extract (30 ug). Lane 1: 0.5 ug/ml NB 400-145; lane 2: 2 ug/ml NB 400-145. ECL: 3 second exposure.](http://images.novusbio.com/fullsize/CD36-Antibody-Western-Blot-NB400-145-img0006.jpg)
![Western Blot: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-31020241618930.jpg)
![Immunocytochemistry/ Immunofluorescence: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-31020241616182.jpg)
![Immunocytochemistry/ Immunofluorescence: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-31020241618949.jpg)
![Immunocytochemistry/ Immunofluorescence: CD36 Antibody - BSA Free [NB400-145] - CD36 ligand disrupts TLR2-CD36 interaction modulated TLR2 heterodimer-signaling. (A) Confocal imaging of central retina cryosection stained with CD11b (white), CD36 (red), TLR2 (green), & DAPI (blue) from blue light-challenged WT mice. Scale bar = 25 μm. (B) High magnification (3X) shows subretinal CD11b-positive cells (white) with the co-localisation of CD36 (red) & TLR2 (green). Scale bar = 5 μm. (C-F) Peritoneal MPs were stimulated with 300 ng/ml R-FSL1 in the presence of 10−7 M MPE-001 or vehicle. (C) MPE-001 disrupted the interaction between CD36 labeled with Cy5 (red) & TLR2 labeled with Cy3 (green) as assessed by FRET after 5 min stimulation with R-FSL1. (D) Percentage of energy transfer measured using LSM-700 confocal microscope (Zeiss). Data in B,C are representative of 3-4 independent experiments. (E) Phosphorylated & total Western blot density bands of IRAK4, IKK alpha beta & P65-NF kappa B, JNK & P38 in peritoneal MPs from CD36+/+ & CD36−/− mice stimulated with R-FSL1. (F) Quantification of P65-NF kappa B following stimulation of CD36+/+ & CD36−/− peritoneal MPs with R-FSL1 using ELISA-based assay. Data in C-F are representative of 3 independent experiments (n = 3/group). In (D,F) one-way ANOVA test with Newman-Keuls post-test for multiple comparison was performed. *P < 0.05, **P < 0.01 & ***P < 0.001 vs R-FSL1. Data are shown as mean ± S.E.M. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31501473), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-145_rabbit-polyclonal-cd36-antibody-310202416173513.jpg)
![Immunohistochemistry: CCR2 Antibody [NBP1-48337] - Localization of CCR1 (binds to CCL8, CCL14, and CCL16), CCR2 (binds to CCL2, CCL8, and CCL16), CCR3 (binds to CCL11), and CXCR3 (binds to CXCL10) in the bovine endometrium and fetal trophoblast obtained from cows in their 18th day of pregnancy. Intensive immunoreactivity was observed in endometrial epithelial cells, glandular epithelial cells, or fetal trophoblast. No positive immunoreactivity was observed in the negative control (Control). Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/18/4/742), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-NBP1-48337-img0017.jpg "Immunohistochemistry: CCR2 Antibody [NBP1-48337] - Localization of CCR1 (binds to CCL8, CCL14, and CCL16), CCR2 (binds to CCL2, CCL8, and CCL16), CCR3 (binds to CCL11), and CXCR3 (binds to CXCL10) in the bovine endometrium and fetal trophoblast obtained from cows in their 18th day of pregnancy. Intensive immunoreactivity was observed in endometrial epithelial cells, glandular epithelial cells, or fetal trophoblast. No positive immunoreactivity was observed in the negative control (Control). Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/18/4/742), licensed under a CC-BY license.")
![Western Blot: CCR2 Antibody [NBP1-48337] - Analysis of CCR2 in rat lysate. Image courtesy of product review submitted by Rasha Elbaz.](http://images.novusbio.com/fullsize/CCR2-Antibody-Western-Blot-NBP1-48337-img0005.jpg)
![Flow Cytometry: CCR2 Antibody - BSA Free [NBP1-48337] - An intracellular stain was performed on U2-OS cells with CCR2 NBP1-48337AF647 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/CCR2-Antibody---BSA-Free-Flow-Cytometry-NBP1-48337-img0020.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human liver cancer using 5 ug/ml concentration of CCR2 antibody. Intense cytoplasmic-membranous immune-staining was observed in the cancerous hepatocytes, whereas the staining was relatively weak in the cells adjacent to the fibrotic areas. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0011.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human rectal adenocarcinoma using 5 ug/ml concentration of CCR2 antibody. The cancerous cells in the section developed a uniform but specific CCR2 immunopositivity whereas a weak staining was seen in the tumor stroma cells. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0012.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE section of human esophageal squamous cell carcinoma (SCC) using 5 ug/ml concentration of CCR2 antibody. Strong cytoplasmic-membranous immune-staining was observed in SCC cells and a relatively weaker staining was seen in the tumor stroma cells. [Magnification 10X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0013.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human normal kidney using 5 ug/ml concentration of CCR2 antibody. Strong cytoplasmic immunostaining was observed in the various renal cells (especially from tubules/ducts epithelium). The cells of Bowman's capsule depicted a very weak cytoplasmic staining for CCR2 protein. [Magnification 10X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0014.jpg)
![Immunohistochemistry-Paraffin: CCR2 Antibody [NBP1-48337] - Analysis of FFPE tissue section of human normal breast using 5 ug/ml concentration of CCR2 antibody. The breast ductal/acinar epithelial cells showed a strong cytoplasmic-membranous CCR2 immune-positivity, whereas the intra-lobular connective tissue depicted weak staining. [Magnification 40X]](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-Paraffin-NBP1-48337-img0015.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48337] - An intracellular stain was performed on THP-1 cells with CCR Antibody NBP1-48337R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48337-img0016.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48337] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48337 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48337-img0018.jpg)
![Flow Cytometry: CCR2 Antibody - BSA Free [NBP1-48337] - An intracellular stain was performed on U2-OS cells with CCR2 NBP1-48337 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/CCR2-Antibody---BSA-Free-Flow-Cytometry-NBP1-48337-img0019.jpg)
![Immunocytochemistry/Immunofluorescence: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - Integrin beta 1 (P4C10) antibody was tested in -20 degree MeOH fixed HeLa cells at a 1:200 dilution against DyLight 488 (green). Actin and nuclei were counterstained against Phalloidin 568 (red) and DAPI (blue), respectively.](http://images.novusbio.com/fullsize/Integrin-beta-1-CD29-Antibody-P4C10-Immunocytochemistry-Immunofluorescence-NBP2-36561-img0001.jpg "Immunocytochemistry/Immunofluorescence: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - Integrin beta 1 (P4C10) antibody was tested in -20 degree MeOH fixed HeLa cells at a 1:200 dilution against DyLight 488 (green). Actin and nuclei were counterstained against Phalloidin 568 (red) and DAPI (blue), respectively.")
![Flow Cytometry: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - An intracellular stain was performed on A431 cells with Integrin beta 1/CD29 [P4C10] Antibody NBP2-36561B (blue) and a matched isotype control (orange). Both antibodies were conjugated to Biotin. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Streptavidin - R-Phycoerythrin Protein (2012-1000, Novus Biologicals).](http://images.novusbio.com/fullsize/Integrin-beta-1-CD29-Antibody-P4C10-Flow-Cytometry-NBP2-36561-img0005.jpg)
![Flow Cytometry: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561]](http://images.novusbio.com/fullsize/Integrin-beta-1-CD29-Antibody-P4C10-Flow-Cytometry-NBP2-36561-img0002.jpg)
![Flow Cytometry: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - A surface stain was performed on HeLa cells with Integrin beta 1/CD29 [P4C10] Antibody NBP2-36561PE (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/Integrin-beta-1-CD29-Antibody-P4C10-Flow-Cytometry-NBP2-36561-img0003.jpg)
![Flow Cytometry: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - A surface stain was performed on HeLa cells with Integrin beta 1/CD29 [P4C10] Antibody NBP2-36561AF488 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/Integrin-beta-1-CD29-Antibody-P4C10-Flow-Cytometry-NBP2-36561-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: Integrin beta 1/CD29 Antibody (P4C10) [NBP2-36561] - Overnight incubation with 1:50 Integrin beta 1/CD29 primary antibody in PBS/BSA 1%, at 4ºC. Green: Integrin beta 1/CD29 Antibody (P4C10), Red: Phalloidin, Blue: DAPI. Image from verified customer review.](http://images.novusbio.com/fullsize/antibody/nbp2-36561_mouse-monoclonal-integrin-beta-1-cd29-antibody-p4c10-immunocytochemistry-immunofluorescence-1462023134549..jpg)
![Western Blot: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Exosome or whole cell lysates (WCL) sample from MDA-MB-231 cells was loaded with 10 ug/lane. 10% SDS-PAGE. CD63 antibody (NBP2-32830) was used for primary antibody: 1:500, 4C, overnight. Image from verified customer review.](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Western-Blot-NBP2-32830-img0020.jpg "Western Blot: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Exosome or whole cell lysates (WCL) sample from MDA-MB-231 cells was loaded with 10 ug/lane. 10% SDS-PAGE. CD63 antibody (NBP2-32830) was used for primary antibody: 1:500, 4C, overnight. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Immunofluorescence: - Azide and BSA Free [NBP2-34689] - IF staining of HeLa cells using AF488 labeled CD63 Monoclonal Antibody (MX-49. 129.5) (green). F-actin filaments are labeled with dylight 554 phalloidin (red) Nuclei stained with DAPI (blue).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunocytochemistry-Immunofluorescence-NBP2-32830-img0011.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Formalin-fixed, paraffin-embedded Mouse spleen stained with CD63 Antibody (MX-49.129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunohistochemistry-Paraffin-NBP2-32830-img0014.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometric analysis of bead-bound exosomes derived from MCF-7 cells. CD63 Mouse Monoclonal antibody (MX-49.129.5) followed by goat anti-mouse IgG-CF568 (orange); unstained exosomes (gray).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0019.jpg)
![Western Blot: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Western Blot: CD63 Antibody (MX-49.129.5) - Azide and BSA Free [NBP2-34689] - Western blot of human spleen Lysate with CD63 Monoclonal Antibody (IMX-49. 129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Western-Blot-NBP2-32830-img0008.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) - Azide and BSA Free [NBP2-34689] - Formalin-fixed, paraffin-embedded human prostate carcinoma stained with CD63 Monoclonal Antibody (MX-49. 129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunohistochemistry-Paraffin-NBP2-32830-img0009.jpg)
![Immunohistochemistry-Paraffin: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Formalin-fixed, paraffin-embedded human melanoma stained with CD63 Antibody (MX-49.129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Immunohistochemistry-Paraffin-NBP2-32830-img0013.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow Cytometry: CD63 Antibody (MX-49.129.5) - Azide and BSA Free [NBP2-34689] - Flow Cytometry of NIH/3T3 Cells. Black: Cells alone; Green: Isotype Control; Red; PE-labeled CD63 Monoclonal Antibody (MX-49. 129.5)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0010.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow Cytometric staining of CD63 on human PBMC cells. Black: cells alone; Green: Isotype Control; Red: PE-labeled CD63 Monoclonal Antibody (MX-49.129.5).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0015.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometry of MCF-7 cells unstained (gray) or stained with CF488A-labeled CD63 monoclonal antibody (MX-49.129.5) (green).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0016.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometry of bead-bound exosomes derived from MCF-7 cells. Unstained exosomes (gray) or stained with CF488A-labeled CD63 monoclonal antibody (MX-49.129.5) (green)](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0017.jpg)
![Flow Cytometry: CD63 Antibody (MX-49.129.5) [NBP2-32830] - Flow cytometric analysis of MCF-7 cells. CD63 Mouse Monoclonal antibody (MX-49.129.5) followed by goat anti-mouse IgG-CF568 (orange); unstained cells (gray).](http://images.novusbio.com/fullsize/CD63-Antibody-MX-49-129-5-Flow-Cytometry-NBP2-32830-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-724-img0004.jpg "Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).")
![Immunohistochemistry-Paraffin: CTGF/CCN2 Antibody [NB100-724] - Analysis of a FFPE tissue section of human lymph node using 1:200 dilution of CTGF/CCN2 antibody (NB100-724). The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunohistochemistry-Paraffin-NB100-724-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analysis of astrocyte reactivity, the cytoskeleton & migration rate following treatment with TGF-beta 2 & CCN2/CTGF. (A) GFAP immunoreactivity (green) is increased in murine ON astrocytes following TGF-beta 2 & CCN2/CTGF treatment. Nuclei are stained with Dapi (blue) (B) Western Blot experiments analyses of alpha -actinin protein synthesis in murine ON astrocytes after the treatment with 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 24 h. Densitometric analyses of Western Blot analyses shows the significant increase in alpha -actinin protein synthesis. Mean value of untreated cells (control) was set at 1. GAPDH was used to normalize protein intensity (n = 4; 50 ng CCN2/CTGF: *p = 0.029; 100 ng CCN2/CTGF: *p = 0.015; unpaired two-tailed t-test). (C) Scratch assay analyses show a significant increased migration rate for murine ON astrocytes after the treatment with ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 12 h. Mean value of migration rate of control cells was set to 100% (control: n = 15; TGF-beta 2: n = 12, **p = 0.008; 50 ng/ml CCN2/CTGF: n = 10, *p = 0.001; 100 ng/ml CCN2/CTGF: n = 4, **p = 0.0001). Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241683912.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415523931.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415535150.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analyses of ECM components in murine ON astrocytes following treatment w/ TGF-beta 2 & CCN2/CTGF. (A) Immunocytochemical staining against fibronectin (green, upper panel) showed a markedly increase following the treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Immunocytochemical staining against tropoelastin (green, lower panel) showed a pronounced increase after treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Nuclei stained w/ Dapi (blue). (B) Real-time RT-PCR analyses shows an intense upregulation of collagen 3 alpha 1, tropoelastin & fibronectin mRNA in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3; TGF-beta 2 ***p = 0.0000004, 50 ngCTGF **p = 0.005, 100ngCTGF **p = 0.008; fibronectin: n = 6, TGF-beta 2 *p = 0.00004, 50 ng CTGF *p = 0.016, 100 ngCTGF *p = 0.05; elastin: n = 5, TGF-beta 2 *p = 0.026, 50 ng CTGF *0.04, 100 ng CTGF *p = 0.03). mRNA expression normalized to Gnb2l & mean value of control cells set at 1. (C) Western Blot analysis show an increase in protein synthesis of collagen 3 alpha 1, elastin & fibronectin in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3, TGF-beta 2 *p = 0.03, 100 ngCTGF **p = 0.009; fibronectin: n = 5, **p = 0.005, 50 ngCTGF **p = 0.006, 100 ng CTGF *p = 0.02; tropoelastin: n = 5, TGF-beta 2 ***p = 0.0004, 50 ngCTGF **p = 0.002, 100 ngCTGF ***p = 0.00001). GAPDH & alpha -tubulin used to normalize protein synthesis & mean value of control cells set at 1. Right panel shows representative Western Blots for all three proteins. Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415532092.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Increasing substratum stiffness causes alterations in murine ON astrocyte reactivity, actin cytoskeleton & CCN2/CTGF level. (A) Filamentous actin labeled by phalloidin (red, upper panel) is increased when murine ON astrocytes were cultured on substrates with higher stiffness (30 kPa, 60 kPa) compared to softer control (10 kPa). Increasing substratum stiffness leads to an enhanced formation of actin stress fibers. Immunoreactivity of CCN2/CTGF (green, middle panel) is markedly increased when murine ON astrocytes were grown on substrates with higher stiffness (30, 60 kPa) compared to softer control (10 kPa). Murine ON astrocytes show an enhanced GFAP protein synthesis (green, lower panel) when cultured on 30 or 60 kPa compared to 10 kPa. Nuclei were stained with Dapi (blue). (B) CCN2/CTGF protein synthesis is significantly increased in murine ON astrocytes grown on 60 kPa compared to 10 kPa (10 kPa: n = 5; 30 kPa: n = 5; 60 kPa: n = 5; *p = 0.04; unpaired two-tailed t-test). (C) Protein synthesis of GFAP (10 kPa: n = 6; 30 kPa: n = 6, **p = 0.005; 60 kPa: n = 4, *p = 0.04; unpaired two-tailed t-test) show an enhanced reactivity of murine ON astrocytes cultured on 30 kPa or 60 kPa compared to 10 kPa control. (D) Vimentin protein synthesis is significantly increased in murine ON astrocytes cultured on 60 kPa compared to 10 kPa (10 kPa: n = 4; 30 kPa: n = 4; 60 kPa: n = 3 ***p = 0.00002). Protein synthesis was normalized to alpha -tubulin & mean value of control (10 kPa) was set at 1. Data represented as mean ± SEM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241612698.jpg)
![Western Blot: LYVE-1 Antibody [NB100-725] - Western Blot: [NB100-725] - Total protein from human stomach, lymph node and placenta was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-LYVE1 in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Western-Blot-NB100-725-img0027.jpg "Western Blot: LYVE-1 Antibody [NB100-725] - Western Blot: [NB100-725] - Total protein from human stomach, lymph node and placenta was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-LYVE1 in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: LYVE-1 Antibody [NB100-725] - Analysis using the DyLight 488 conjugate of NB100-725. Staining of LYVE1 in paraffin embedded MDA-MB-231 breast cancer orthotopic transplantation tissue. Image courtesy of product review submitted by Luana Schito.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-Paraffin-NB100-725-img0028.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human lung blood vessels using NB100-725. Note presence of RBCs within vessel lumen.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0011.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - Analysis using the DyLight 488 conjugate of NB100-725. Unlabeled control with labeled samples of cells dissociated mechanically and enzymatically from human skin. Image provided via product review by Patricia Redondo.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0024.jpg)
![Western Blot: LYVE-1 Antibody [NB100-725] - Analysis of extracts from A549 cells using LYVE1 antibody (NB100-725, 1:100). Image from verified customer review.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Western-Blot-NB100-725-img0018.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - LYVE1 antibody was tested at 1:400 in A549 cells using an Alexa Fluor 488 secondary (shown in green) alongside unstained cells (shown in red).](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0016.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on A549 cells with LYVE-1 Antibody NB100-725 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0031.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human bladder vasculature using NB100-725.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0012.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human lung blood vessels using NB100-725.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0013.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - Analysis using the Alexa Fluor (R) 488 conjugate of NB100-725. Staining of LYVE1 in human dissociated skin lyve1+ using AF488 conjugated anti-LYVE1 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0023.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on A549 cells with LYVE-1 Antibody NB100-725G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Dylight 488.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0029.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on K562 cells with LYVE-1 Antibody NB100-725C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0030.jpg)
![Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Western-Blot-NB100-78039-img0006.jpg "Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.")
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Human tonsil tissue stained with PSGL-1/CD162 Antibody (HECA-452) at 5ug/mL, and Leica Refine DAB kit. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PSGL-1-CD162-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0014.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD3+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody [F0101B, R&D Systems]. A co-stain was performed using CD3 antibody NBP2-25186APC.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0008.jpg)
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - IHC analysis of formalin-fixed paraffin-embedded tissue section of human breast adenocarcinoma using CLA antibody (clone HECA-452) at 5 ug/ml concentration. The antibody generated a membrane-cytoplasmic staining in the cancerous cells of breast adenocarcinoma. Note:- Besides lymphocytes, CLA has been shown to be present on cells of normal endometrium as well as breast cancer tissues (PMID 19625313 and 22970241).](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0004.jpg)
![Flow Cytometry: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Human peripheral blood lymphocytes stained with purified HECA-452, followed by anti-mouse IgG FITC](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cytometry-NB100-78039-img0005.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD14+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by rat-Dylight 488 conjugated secondary antibody. A co-stain was performed using CD14 antibody NB100-77758AF488.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0007.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48338] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48338G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48338-img0004.jpg "Flow Cytometry: CCR2 Antibody [NBP1-48338] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48338G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 488.")
![Immunocytochemistry/Immunofluorescence: CCR2 Antibody [NBP1-48338] - Analysis of CCR2 in NIH/3T3 cells.](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-48338-img0003.jpg)
![Immunohistochemistry: CCR2 Antibody [NBP1-48338] - Expression patterns of CCL2 and CCR2 in unwounded and wounded corneas of WT and MMP12 KO mice. Immunofluorescence of CCL2 chemokine receptor CCR2 in unwounded and chemically wounded (2-days after injury) WT and Mmp12-/- mouse corneas. Control images represent mouse corneas stained with secondary antibody only and without primary antibody. Nuclei were visualized by staining with DAPI (blue). Scale bars: 50 um. CCR2 staining was visualized in epithelial and stromal layers of unwounded and wounded WT and Mmp12-/- corneas. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-47831-z), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCR2-Antibody-Immunohistochemistry-NBP1-48338-img0007.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48338] - An intracellular stain was performed on THP-1 cells with CCR2 Antibody NBP1-48338F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48338-img0006.jpg)
![Flow Cytometry: CCR2 Antibody [NBP1-48338] - The Alexa Fluor 488 conjugate of this antibody was used: Mouse peripheral blood mononuclear cells were unstained (left) or stained (right) with CCR2 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/CCR2-Antibody-Flow-Cytometry-NBP1-48338-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: CCR2 Antibody - BSA Free [NBP1-48338] - Expression patterns of CCL2 & CCR2 in unwounded & wounded corneas of WT & MMP12 KO mice. (A) Immunofluorescence of CCL2 chemokine & (B) its receptor CCR2 in unwounded & chemically wounded (2-days after injury) WT & Mmp12−/− mouse corneas. Control images represent mouse corneas stained with secondary antibody only & without primary antibody. Nuclei were visualized by staining with DAPI (blue). Scale bars: 50 µm. A magnified image of a wounded WT cornea shows perinuclear expression of CCL2 (orange box). CCL2 staining was visualized in epithelial, stromal, & endothelial layers of wounded WT & Mmp12−/− corneas. CCR2 staining was visualized in epithelial & stromal layers of unwounded & wounded WT & Mmp12−/− corneas. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31399604), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-48338_rabbit-polyclonal-ccr2-antibody-310202415175260.jpg)
![Immunocytochemistry/Immunofluorescence: CD19 Antibody (CB19) [NBP2-25196] - CD19 antibody (CB19) was tested in Non-Hodgkin's lymphoma cells at 1:200 dilution. Green: Alexa Flour 488. Image from verified customer review.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Immunocytochemistry-Immunofluorescence-NBP2-25196-img0014.jpg "Immunocytochemistry/Immunofluorescence: CD19 Antibody (CB19) [NBP2-25196] - CD19 antibody (CB19) was tested in Non-Hodgkin's lymphoma cells at 1:200 dilution. Green: Alexa Flour 488. Image from verified customer review.")
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on Ramos cells with CD19 Antibody (CB19) NBP2-26646 (blue) and a matched isotype control (orange). Cells were incubated in an antibody dilution of 2.5 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CD19 Antibody (CB19) [NBP2-25196] - The CD19 (CB19) antibody was tested in Daudi cells at a 1:40 dilution against Dylight 488 (Green). Actin and nuclei were counterstained against Phalloidin 568 (Red) and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Immunocytochemistry-Immunofluorescence-NBP2-25196-img0002.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Surface staining of 10^6 human lymphocytes using 0.2 ug of CD19 antibody (red) and isotype control (green). Cell surface staining kit was used for this test.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0001.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the FITC conjugate of NBP2-25196. Staining of CD19 in 10^6 human lymphocytes using 10 ul (0.25 ug) of this antibody. Shaded histogram represents cells without antibody; green represents isotype control ; red represents anti-CD19 antibody.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0007.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the PE conjugate of NBP2-25196. Staining of CD19 in 1x10^6 human PBMC using 10 ul (0.25 ug) of was used to test this product. Propidium iodide negative lymphocyte population gated for analysis.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0008.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the Alexa Fluor (R) 700 conjugate of NBP2-25196. Staining of human PBMC. Image from verified customer review.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0009.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - Analysis using the DyLight 405 conjugate of NBP2-25196. Staining of CD19 in human PBMCs using anti-CD19 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0010.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on human peripheral blood lymphocytes with TACI/TNFRSF13B/CVID (1A1) antibody NB600-1189PE and a matched isotype control. Cells were incubated in an antibody dilution of 2 ug/mL for 20 minutes at room temperature. A co-stain was performed with NBP2-25196AF647.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0011.jpg)
![Flow Cytometry: CD19 Antibody (CB19) [NBP2-25196] - A surface stain was performed on human peripheral blood lymphocytes with CD9 (HI9a) antibody NB100-77915AF647 and a matched isotype control NBP2-27287AF488. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. A co-stain was performed with NBP2-26646.](http://images.novusbio.com/fullsize/CD19-Antibody-CB19-Flow-Cytometry-NBP2-25196-img0012.jpg)
![Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) MDA-MB-231 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.](http://images.novusbio.com/fullsize/CD44-Antibody-Western-Blot-NBP1-31488-img0031.jpg "<b>Biological Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) MDA-MB-231 whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.")
![<b>Biological Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) HeLa whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody. The observed M.W. is different from the predicted size. It is possibly due to post-translational modifications.](http://images.novusbio.com/fullsize/CD44-Antibody-Western-Blot-NBP1-31488-img0033.jpg)
![Immunocytochemistry/Immunofluorescence: CD44 Antibody [NBP1-31488] - Analysis of methanol-fixed HeLa, using CD44 antibody (Green) at 1:500 dilution. Alpha-tubulin filaments were labeled with an alpha Tubulin antibody (Red) at 1:2000.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-31488-img0016.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human cervical carcinoma. CD44 stained by CD44 antibody diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0036.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human endometrial carcinoma. CD44 antibody diluted at 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0026.jpg)
![Immunohistochemistry-Paraffin: CD44 Antibody [NBP1-31488] - Human pancreatic tumor, using CD44 antibody at 1:100 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/CD44-Antibody-Immunohistochemistry-Paraffin-NBP1-31488-img0035.jpg)
![Immunocytochemistry/ Immunofluorescence: CD44 Antibody [NBP1-31488] - CD44 antibody detects CD44 protein at cell membrane by immunofluorescent analysis.Sample: A431 cells were fixed in ice-cold MeOH for 5 min.Green: CD44 stained by CD44 antibody (NBP1-31488) diluted at 1:500.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-91020242091445.jpg)
![Western Blot: CD44 Antibody [NBP1-31488] - Untreated (-) and treated (+) HeLa whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with CD44 antibody (NBP1-31488) diluted at 1:45000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-910202420104431.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Non-transfected (–) and transfected (+) Wild-type (WT) and G CD44 knockout (KO) HeLa cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody diluted at 1:7000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-1610202419405756.jpg)
![<b>Orthogonal Strategies Validation. </b>Western Blot: CD44 Antibody [NBP1-31488] - Various whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with CD44 antibody diluted at 1:5000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody. Corresponding RNA expression data for the same cell lines are based on Human Protein Atlas program.](http://images.novusbio.com/fullsize/nbp1-31488_rabbit-polyclonal-cd44-antibody-1610202419414564.jpg)
